Microneedle Patches: Device, Combination Product, or Cosmetic? Planning Your First Human Study

Short answer: It depends on three things: what you claim the patch does, how far the needles are designed to go into the skin, and whether a drug or biologic is part of the product. Under guidance from the US Food and Drug Administration (FDA), a microneedle product that claims or is designed to penetrate past the stratum corneum into living skin generally meets the device definition. Once a drug or biologic is coated on, loaded into or packaged with the patch, it may be a combination product, and FDA decides which center leads. The registered-cosmetic route fits only a product that stays on the skin surface and makes appearance claims. The cosmetic definitions in Central America, Panama and Chile are all written around superficial or external application. Settle the category before you write the protocol for your first-in-human (FIH) study, because it decides which dossier the ethics committee and health authority will expect.

Why the category question comes first

Microneedle patches sit on three regulatory borders at once: device and drug, device and biologic, and device and cosmetic. For a startup, the category drives almost everything that follows: which FDA center reviews the product, which investigational application applies in the US, what manufacturing evidence an ethics committee asks for, and whether a polymer-only version and a later drug-loaded version can be treated as the same product.

The rest of this post walks through the US framework first, because most sponsors plan to use FIH data from Latin America in an FDA submission. It then covers the cosmetic and device definitions in Central America, Panama and Chile.

How FDA draws the device line for microneedling products

FDA’s guidance Regulatory Considerations for Microneedling Products (FDA guidance page; PDF) is the clearest US statement. It defines the stratum corneum as “a dead cell layer of skin, as opposed to living layers of skin.” It then says FDA considers claims or statements “that indicate penetration or some effect beyond the stratum corneum into living layers of skin” to be evidence of intent to affect the structure or function of the body. That intent is what makes a product a device under section 201(h) of the Federal Food, Drug, and Cosmetic Act (FD&C Act).

Claims are not the only test. The same guidance says FDA considers “needle penetration beyond the stratum corneum as a result of the design or technology” of a product as evidence that it may be a device. FDA lists what it may look at: needle length and arrangement, needle sharpness, and the degree of control over “depth of penetration into living layers of skin” (FDA microneedling guidance, section IV). In practice, your design specifications and directions for use can classify the product even if your marketing copy is careful.

The guidance also describes products that are generally not devices: microneedling products “that do not penetrate living skin” and claim only to facilitate exfoliation, improve the appearance of skin, give skin a smoother look and feel, or give skin a luminous look. FDA adds that such products “may still be subject to other requirements of the FD&C Act” (FDA microneedling guidance, section V).

For devices, aesthetic microneedling is classified at 21 CFR 878.4430 (Code of Federal Regulations, CFR) as Class II with special controls. The identification text matters for patch developers: it “does not include devices intended for transdermal delivery of topical products such as cosmetics, drugs, or biologics.” A patch built to deliver an active ingredient is therefore outside that classification by its own terms.

When a drug-loaded patch becomes a combination product

FDA’s microneedling guidance excludes products used with topically applied substances such as “creams, ointments, gels, vitamin solutions, drugs, or blood products.” It says these “may be combination products under 21 CFR 3.2(e)”, that they are “outside the scope of this guidance”, and that manufacturers should contact the Office of Combination Products (OCP) (FDA microneedling guidance, section III).

The definition at 21 CFR 3.2(e) covers several configurations that map onto patch programs:

• Single entity. Two or more regulated components “physically, chemically, or otherwise combined or mixed and produced as a single entity” (3.2(e)(1)). Coated, drug-loaded or dissolving microneedles usually raise this question.
• Co-packaged. “Two or more separate products packaged together in a single package or as a unit” (3.2(e)(2)), such as a needle array sold in a kit with a serum.
• Cross-labeled. Separately packaged products whose labeling or investigational plan says they are for use only with a specified drug, device or biologic, where both are required for the intended effect (3.2(e)(3) and (4)).

FDA’s page on combination product types lists a microneedle “patch” as a common example of a prefilled drug delivery system, and a “microneedle patch pre-loaded with biological product” as an example of a prefilled biologic delivery system.

Which FDA center leads depends on the primary mode of action (PMOA). Under 21 CFR 3.2(m), the PMOA is “the single mode of action of a combination product that provides the most important therapeutic action.” Depending on the answer, the lead is the Center for Devices and Radiological Health (CDRH), the Center for Drug Evaluation and Research (CDER) or the Center for Biologics Evaluation and Research (CBER). If the answer is unclear, 21 CFR 3.7 provides a formal request for designation (RFD) and says “a sponsor should file a request for designation before filing any application for premarket review, whether an application for marketing approval or a required investigational notice.” For an FIH plan, that means the jurisdiction question belongs before the US investigational filing, not after the first human data are in.

The “blank patch first” plan

A common development plan is to run the first human study with a polymer-only patch and add an active ingredient later. The sources above support a few cautious points:

• A polymer-only patch is assessed on its own claims and design. If its needles are designed to reach living epidermis or dermis, FDA’s guidance points toward the device definition.
• Once an active is added, the product has to be assessed again under 21 CFR 3.2(e). The loaded patch may be a different regulated product with a different lead center.
• How far data from the blank patch can support the loaded product is a question for FDA, not an assumption. Put it to the agency early, either to OCP or in a Q-Submission (Q-Sub) meeting request.

Write both versions into your regulatory plan from the start, and keep the FIH protocol’s claims about the blank patch consistent with the later program. A safety claim written loosely for the first study can complicate the classification of the second.

The registered-cosmetic route: what it covers in Latin America

Some sponsors ask whether a patch can be registered as a cosmetic and tested that way. The answer turns on the local cosmetic definition, and those definitions are narrow.

Costa Rica and El Salvador: the Central American cosmetics regulation

Central American cosmetic registration follows the Central American Technical Regulation (RTCA, Reglamento Técnico Centroamericano) RTCA 71.03.35:21, adopted by the Council of Ministers of Economic Integration (COMIECO) in Resolución No. 474-2023 (COMIECO-EX). The Secretariat for Central American Economic Integration (SIECA) lists the resolution as in force (SIECA). The resolution states that it entered into force on 5 February 2024.

Its definition (section 4.11) covers products “destinado a ser puesto en contacto con las diversas partes superficiales del cuerpo humano (epidermis, sistemas piloso y capilar, uñas, labios y órganos genitales externos)” for cleaning, perfuming, changing appearance, correcting body odor or protecting them. El Salvador published the regulation in its Diario Oficial (copy hosted by the Superintendencia de Regulación Sanitaria, SRS). Costa Rica’s Ministerio de Salud links the resolution from its cosmetic registration page.

Panama

Panama’s Ministry of Health (MINSA, Ministerio de Salud) states that Ley 419 of 1 February 2024 replaced (“subroga”) Ley 1 of 2001, and that Executive Decree 27 of 10 May 2024 regulates it. According to the same MINSA document, Article 192 of that decree says cosmetic registration and labeling follow the RTCA for cosmetic products (MINSA, DNFD presentation, May 2024). The National Directorate of Pharmacy and Drugs (DNFD, Dirección Nacional de Farmacia y Drogas) puts the line plainly: “Los productos cosméticos solo están indicados para uso tópico. No se ingieren, inhalan o inyectan dentro del cuerpo humano.” It adds that a cosmetic attributed therapeutic properties “debe registrarse como medicamento” (DNFD explainer). The exact definition article in Ley 419 should be confirmed per study.

Chile

Chile’s cosmetics regulation, Decreto Supremo (DS) 239 of 2002 (BCN), defines a cosmetic as a preparation “que se destine a ser aplicado externamente al cuerpo humano”, with only local action or, if absorbed, “carezca de efecto sistémico”. The Instituto de Salud Pública (ISP) repeats that definition in its technical guide on borderline medical devices (Guía Técnica sobre Dispositivos Médicos Frontera, October 2022). The same guide sets the device condition that the product does not achieve “su acción principal en o sobre el cuerpo humano por mecanismos farmacológicos, inmunológicos o metabólicos.” Where a sponsor is unsure, the guide says to seek a ruling (“pronunciamiento”) from the ISP’s Comité de Régimen de Control Sanitario. See also the ISP cosmetics page.

What this means for a patch

A patch whose needles are designed to reach living tissue, or that delivers an active for a therapeutic or structure-or-function effect, is hard to fit inside any of these definitions. Cosmetic registration is a marketing authorization for a cosmetic. It does not authorize a clinical investigation of a device, drug or combination product, and it will not help an FDA submission that depends on device or drug data. Whether consumer-use or claims testing of a genuinely cosmetic product needs ethics review differs by country and should be confirmed per study.

How the category changes your FIH study

Practical steps before you write the protocol

1. Write down the intended use and every claim you plan to make, including in the consent form and instructions for use.
2. Document the design facts FDA says it may weigh: needle length, arrangement, sharpness and control of penetration depth.
3. If any active ingredient is involved, map the product against 21 CFR 3.2(e), state your PMOA reasoning and decide whether to contact OCP or file an RFD before any US investigational filing.
4. Ask FDA how it will view FIH data generated in Latin America. For a device study, plan to meet 21 CFR 812.28.
5. Check the category in each target country. In Chile, the ISP categorization route is in the borderline-device guide; elsewhere, confirm per study with the health authority.
6. Keep the category consistent across protocol, investigator brochure, labeling and consent. Ethics committees notice when documents describe the product differently.

Where bioaccess® fits

bioaccess® runs first-in-human and early feasibility medical device studies in Latin America. For borderline products such as microneedle patches, we work through the category question country by country with the sponsor’s regulatory team before anything is submitted, so the protocol, the ethics dossier and the later FDA plan tell the same story.

Related reading

• Running a First-in-Human Dermatology or Aesthetic Device Trial in Latin America: Sites, PIs and Outpatient Clinics
• Healthy Volunteers in Device FIH Studies: What Ethics Committees Allow on Compensation in Costa Rica, El Salvador, Panama and Chile
• 10 Startup Mistakes That Delay a Latin America FIH Study (and How to Avoid Them)
• Medical device combination products: a tutorial on regulations and compliance
• FDA Q-Submission: what to send before your IDE filing
• FDA foreign clinical data and 21 CFR 812.28 for Latin America studies
• Early feasibility vs pivotal trial
• Preclinical testing before a device FIH study in Latin America
• Fitzpatrick skin type diversity in clinical trials

FAQ

Is a microneedle patch a medical device?

Often, but not always. FDA guidance treats claims or design features that indicate penetration beyond the stratum corneum into living layers of skin as evidence that a microneedling product is a device. A product that does not penetrate living skin and makes only appearance or exfoliation claims would generally not be a device.

When does a microneedle patch become a combination product?

When a drug or biologic is combined with it as a single entity, packaged with it, or cross-labeled for use only with it, as described in 21 CFR 3.2(e). FDA lists a microneedle patch as a common example of a prefilled drug delivery system and of a prefilled biologic delivery system.

Who decides which FDA center reviews a drug-loaded patch?

FDA assigns the lead center based on the primary mode of action. If the answer is unclear, a sponsor can file a request for designation under 21 CFR 3.7, which says the request should be filed before any premarket application or required investigational notice.

Can a microneedle patch be registered as a cosmetic in Central America, Panama or Chile?

Only if it genuinely fits the cosmetic definition. RTCA 71.03.35:21 covers products in contact with superficial parts of the body, Panama’s DNFD says cosmetics are not injected into the body, and Chile’s DS 239 covers products applied externally. A patch designed to reach living tissue or deliver an active is hard to fit inside these definitions.

Does cosmetic registration let me run a clinical study of my patch?

No. Cosmetic registration is a marketing authorization for a cosmetic. A clinical investigation of a device, drug or combination product needs ethics committee approval and, where required, health authority authorization in each country. Whether claims testing of a true cosmetic needs ethics review should be confirmed per study.

Can I run my first study with a polymer-only patch and add the drug later?

Many teams plan it that way, but the loaded patch has to be assessed again as a possible combination product. How far data from the blank patch can support the loaded product is a question to put to FDA early, through the Office of Combination Products or a Q-Submission.